Skip to main content

In this Issue

  • Segmentation on the horizon

    Retailers were preparing for the imminent launch of Chattem’s Nasacort Allergy 24HR nasal spray (triamcinolone intranasal) last month, clearing out quite a bit of shelf space for the new allergy remedy.

    (For the full category review, including sales data, click here.)

  • Shoppers respond to convenience, brands

    Mintel projects the pet products category will grow an average of 3.8% over the next five years to nearly $13.7 billion by 2017.

    (For the full category review, including sales data, click here.)

  • Pharmacy’s future in sync with technology

    Where is pharmacy automation headed, and how will it be put to use by pharmacists and the companies that employ them?

  • Prevention key as people forgo sick days

    Prevention. That’s currently one of the predominant themes in cough-cold. Perhaps it’s a sign of the times. With the economy still undergoing a slow recovery, 90% of workers recently reported they would opt to report to work sick vs. calling out, according to the fourth annual Flu Season Survey from Staples.

  • Mass trades fragrance for bath scents

    Is the smell of money in the air for the fragrance market? Perhaps.

    (For the full category review, including sales data, click here.)

  • Adherence gets some stickiness

    “No one gets paid unless patients improve adherence.”

    That’s what Aaron McKethan, SVP of strategy and business development for RxAnte, had to say in a Jan. 13 article on Forbes.com, “A digital health acquisition to watch.” The story focused largely on RxAnte’s recent acquisition by Millennium Laboratories in December — which the author described as a “little-known, private equity-backed urine drug testing company” — and the technology it uses to improve patient adherence.

  • Mapping out the next generics wave

    From 2012 to 2017, global spending on medicines will increase from $205 billion to $235 billion, according to IMS Health. By 2017, 36% of the spend will be on generics, a number that is 9% more than the percentage in 2013.

    As a result of the patent cliff, generic drug manufacturers have thrived while branded pharmaceutical manufacturers have suffered. Branded pharmaceutical manufacturers are expected to suffer even more in the coming years, as many more important patents will lose exclusivity.

X
This ad will auto-close in 10 seconds